Ribosome display and selection of human anti-cD22 scFvs derived from an acute lymphocytic leukemia patient.
Novel in vitro methods for the display of antibody libraries against disease-related antigens have led to the development of powerful protein-based biotherapeutics. Eukaryotic ternary ribosome complexes can be used to display human single chain antibodies (scFvs) to isolate specific binding reagents to these antigens. Here, we present the isolation of human scFv against the immunotherapeutic target antigen CD22 from a patient-derived human scFv library using ribosome display technology. The ribosome complexes were enriched against the extra-cellular domain of human CD22 conjugated to magnetic beads. Isolated constructs were further affinity-matured and specific binding activity was demonstrated by surface plasmon resonance and validated using in vitro cell assays. The isolated human anti-CD22 scFvs can provide a basis for the development of new immunotherapeutic strategies in CD22-expressing malignant diseases.
Rothe
Achim
A
CSIRO Molecular and Health Technologies, 343 Royal Parade, Parkville, Victoria 3052, Australia. achim.rothe@uk-koeln.de
Nathanielsz
Anne
A
Oberhäuser
Frank
F
von Pogge
Strandmann Elke
SE
Engert
Andreas
A
Hudson
Peter J
PJ
Power
Barbara E
BE
D000906:Antibodies / Q000276:immunology*; D000915:Antibody Affinity / Q000276:immunology; D000918:Antibody Specificity / Q000276:immunology; D002460:Cell Line; D006801:Humans; D007128:Immunoglobulin Fragments / Q000276:immunology; D054198:Precursor Cell Lymphoblastic Leukemia-Lymphoma / Q000276:immunology*; D012270:Ribosomes / Q000276:immunology*; D051918:Sialic Acid Binding Ig-like Lectin 2 / Q000276:immunology*; D020349:Surface Plasmon Resonance
D000906:Antibodies; D007128:Immunoglobulin Fragments; D051918:Sialic Acid Binding Ig-like Lectin 2